Olathe, Kan., Aug. 4, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ECI-OSA-11, the company’s T cell-based immunotherapy for the treatment of osteosarcoma, a common form of canine cancer for which there is no cure. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. The trial will be conducted at the University of Missouri, Columbia College of Veterinary Medicine. ECI-OSA-11 is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. The patient will have surgery to remove their osteosarcoma and then will be treated with ECI-OSA-11 to eliminate cancer cells that remain following surgery. The objective of this clinical trial is to determine whether ECI-OSA-11 [...]